PharmaPoint:人類乳突病毒(HPV)預防疫苗 - 美國的醫藥品的預測與市場分析
PharmaPoint: Prophylactic Human Papillomavirus Vaccines - US Drug Forecast and Market Analysis to 2022
|出版日期||內容資訊||英文 94 Pages
|PharmaPoint:人類乳突病毒(HPV)預防疫苗 - 美國的醫藥品的預測與市場分析 PharmaPoint: Prophylactic Human Papillomavirus Vaccines - US Drug Forecast and Market Analysis to 2022|
|出版日期: 2014年03月31日||內容資訊: 英文 94 Pages||
The first prophylactic vaccine for immunization against human papillomavirus (HPV) became available in 2006. The global HPV vaccines market is now well established, yet vaccine coverage rates amongst the traditional target population of adolescent girls remain persistently low. Initially HPV vaccines were developed and marketed solely to protect against cervical cancer. In recent years the role of HPV in other cancers has been increasingly recognized which has facilitated a shift towards vaccinating a wider population, most significant has been the inclusion of males in routine vaccine recommendations in some countries. The current HPV vaccines market is dominated by one major player, Merck's Gardasil, with GlaxoSmithKline's (GSK's) HPV vaccine Cervarix providing the only competition. The introduction of Merck's nine-valent vaccine (V503) is set to change the future landscape of the HPV vaccines sector.
In the US the total number of HPV vaccine doses delivered annually is likely to grow steadily over the next few years, as more males receive vaccination and Merck's nine-valent vaccine V503 becomes available in 2015. US market growth will contribute to global growth in the HPV vaccines sector. There is no indication that coverage rates for adolescent girls will increase dramatically over the forecast period, as they have been relatively stable over the past few years. However, a modest increase will likely be achieved following the introduction of V503, which will be accompanied by a marketing and awareness campaign.